This study analyzed the efficacy and adverse reactions of pyrotinib combined with capecitabine compared with trastuzumab combined with capecitabine and discussed the effect and safety of pyrotinib combined with capecitabine in HER-2 positive breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.